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Introduction
Cryopyrin-associated periodic syndrome (CAPS) is an
inherited disease which is caused by gain-of function
mutations in CIAS1 gene function resulting in increased
secretion of active IL-1b. IL-1b also can stimulate the
production of other proinflammatory cytokines, such
as IL-6, TNFa and so on (downstream cascade). The
use of IL-1 blockers dramatically controls inflamma-
tion in CAPS patients and provide a persistent ameli-
oration of the inflammatory manifestations. The data
about using of IL-6 or TNFa blockers in CAPS are
very limited.
Objectives
The aim of our retrospective study was to describe the
effects of IL-6 and TNFa blockers in CINCA/NOMID
syndrome.
Methods
We describe the effects of IL-6 and TNFa blockers in
4 patients with CINCA/NOMID syndrome who were
treated in their local hospitals by tocilizumab (n=2), inflixi-
mab (n=1) and adalimumab (n=1). Patient#1 (Pt1) with
CINCA/NOMID was treated by TCZ due to lack of access
to IL-1 blockers, Pt2 was misdiagnosed as systemic JIA
and received TCZ, Pt3 was misdiagnosed as Crohn’s
disease and was treated by the infliximab and Pt4 was
misdiagnosed as a TRAPS and was treated by adalimumab.
All patients had concomitant corticosteroids (CS).
Results
In Pt1 an initial clinical and laboratory response was
observed after the first infusion (no fever, no rash). How-
ever 2 week after the first infusion the patients had a
relapse of the disease. . The second infusion was less effec-
tive, leading to a partial clinical response with persistent
elevation of acute phase reactants (CRP, ESR) and WBC.
The third infusion was ineffective and associated with
infusion reaction and TCZ was stopped.
In Pt2 TCZ was initiated after CS and methotrexate fall.
During TCZ course fever and rash decreased but not dis-
appeared, CRP, SAA and ESR were normalized but no
changes in ear (senso-neural deafness), eye (conjunctivitis
and uveitis) and brain damage (morning headaches with
vomiting). Steroids were tapered but not discontinued due
to flares of the disease.
In Pt3 two initial Infliximab infusions (every 2 weeks)
were effective: no fever, no rash and normalized CRP and
ESR. It was difficult to evaluate any changes in the organs
damage due to small age of child. After 2nd infliximab
infusion Pt3 experienced the flare and 3rd infliximab infu-
sion was ineffective and discontinued. Steroids were
tapered but not discontinued due to flare of the disease.
In Pt4 adalimumab (40 mg sc every 2 weeks) was inef-
fective: only short-term decreasing of CRP and ESR. Girl
still had all features of the disease and really controlled by
only CS. She had impressive linear growth delay, open
fontanels, hydrocephaly, chronic meningitis and acute
phase reactants.
Later Pt2, 3, 4 were assessed by authors of this abstract
and the CINCA/NOMID syndrome was diagnosed
by clinically (n=3) and genetically (n=2, 1-negative
mutations). Canakinumab was initiated in all children and
provided prompt anti-inflammatory effect.
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Conclusion
The failure of anti-IL-6 and anti-TNFa treatment in
CAPS patients confirms the dominant role of IL-1 in
the pathogenesis of the disease and only IL-1 blockers
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